Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?
作者信息
Ommen S R, Nishimura R A, Edwards W D
出版信息
Heart. 2003 Aug;89(8):929-30. doi: 10.1136/heart.89.8.929.
Abstract
摘要
相似文献
1
Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?法布里病：会是梗阻性肥厚型心肌病的一种伪装吗？
Heart. 2003 Aug;89(8):929-30. doi: 10.1136/heart.89.8.929.
2
Female Anderson--Fabry disease mimicking hypertrophic cardiomyopathy.表现为肥厚型心肌病的女性安德森-法布里病。
J Clin Pathol. 2012 Apr;65(4):377-8. doi: 10.1136/jclinpath-2011-200166. Epub 2011 Nov 2.
3
[Fabry disease among hypertrophic cardiomyopathy of genetic origin].[遗传性肥厚型心肌病中的法布里病]
Rev Med Interne. 2010 Dec;31 Suppl 2:S233-7. doi: 10.1016/S0248-8663(10)70019-9.
4
Fabry Disease and/or Hypertrophic Cardiomyopathy.法布里病和/或肥厚型心肌病。
Int Heart J. 2017 May 31;58(3):305-306. doi: 10.1536/ihj.17-142. Epub 2017 May 23.
5
[Report from the 8th Tohoku Chapter Educational Seminar: a case of hypertrophic cardiomyopathy with respiratory failure].[第八届东北分会教育研讨会报告：一例肥厚型心肌病合并呼吸衰竭病例]
Nihon Naika Gakkai Zasshi. 2012 Oct 10;101(10):2988-96. doi: 10.2169/naika.101.2988.
6
Fabry disease in patients with hypertrophic cardiomyopathy (HCM).肥厚型心肌病（HCM）患者中的法布里病。
Z Kardiol. 2002 Dec;91(12):992-1002. doi: 10.1007/s00392-002-0870-7.
7
Hypertrophic obstructive cardiomyopathy due to Fabry's disease.法布里病所致肥厚型梗阻性心肌病
N Engl J Med. 1982 Oct 7;307(15):926-8. doi: 10.1056/NEJM198210073071505.
8
A mimic of hypertrophic cardiomyopathy.肥厚型心肌病的一种模仿疾病。
Eur Heart J. 2015 Mar 21;36(12):763. doi: 10.1093/eurheartj/ehu474. Epub 2014 Dec 17.
9
[An autopsy case of Fabry's disease manifesting ileus].[1例表现为肠梗阻的法布里病尸检病例]
Nihon Shokakibyo Gakkai Zasshi. 1991 Dec;88(12):2898-903.
10
Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.日本诊断为肥厚型心肌病的男性患者中法布里病的患病率及临床特征
J Cardiol. 2017 Jan;69(1):302-307. doi: 10.1016/j.jjcc.2016.05.014. Epub 2016 Aug 21.
引用本文的文献
1
HCM-Echo-VAR-Ensemble: Deep Ensemble Fusion to Detect Hypertrophic Cardiomyopathy in Echocardiograms.HCM-超声心动图-变量-集成模型：用于在超声心动图中检测肥厚型心肌病的深度集成融合模型
IEEE Open J Eng Med Biol. 2024 Oct 25;6:193-201. doi: 10.1109/OJEMB.2024.3486541. eCollection 2025.
2
The Asian Fabry Cardiomyopathy High-Risk Screening Study 2 (ASIAN-FAME-2): Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy.亚洲法布里心肌病高危筛查研究2（ASIAN-FAME-2）：左心室肥厚患者中法布里病的患病率
J Clin Med. 2024 Jul 2;13(13):3896. doi: 10.3390/jcm13133896.
3
Zebras Exist, Too!斑马也存在！
Arq Bras Cardiol. 2024 Mar 8;121(1):e20230834. doi: 10.36660/abc.20230834. eCollection 2024.
4
Difficulties in Diagnosing Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy (LVH): Is the Novel GLA Gene Mutation a Pathogenic Mutation or Polymorphism?不明原因左心室肥厚（LVH）患者中诊断法布里病的困难：新的GLA基因突变是致病突变还是多态性？
Balkan J Med Genet. 2023 Jul 31;26(1):43-50. doi: 10.2478/bjmg-2023-0010. eCollection 2023 Jul.
5
The Frequency of Fabry Disease in Patients with Cardiac Hypertrophy of Various Phenotypes Including Prominent Papillary Muscle: The TUCARFAB Study in Turkey.土耳其 TUCARFAB 研究：包括显著乳头肌在内的各种表型心脏肥厚患者中 Fabry 病的频率。
Anatol J Cardiol. 2023 Apr;27(4):223-228. doi: 10.14744/AnatolJCardiol.2022.2503.
6
Importance of Echocardiography and Clinical "Red Flags" in Guiding Genetic Screening for Fabry Disease.超声心动图及临床“警示信号”在指导法布里病基因筛查中的重要性
Front Cardiovasc Med. 2022 Apr 25;9:838200. doi: 10.3389/fcvm.2022.838200. eCollection 2022.
7
Application of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies.应用患者特异性 iPSCs 对 X 连锁型扩张型心肌病的建模和治疗。
Int J Mol Sci. 2021 Jul 29;22(15):8132. doi: 10.3390/ijms22158132.
8
High Prevalence of Late-Onset Fabry Cardiomyopathy in a Cohort of 499 Non-Selective Patients with Left Ventricular Hypertrophy: The Asian Fabry Cardiomyopathy High-Risk Screening Study (ASIAN-FAME).499例非选择性左心室肥厚患者队列中迟发性法布里心肌病的高患病率：亚洲法布里心肌病高危筛查研究（ASIAN-FAME）
J Clin Med. 2021 May 17;10(10):2160. doi: 10.3390/jcm10102160.
9
Serial Analysis of Cardiopulmonary Fitness and Echocardiography in Patients with Fabry Disease Undergoing Enzyme Replacement Therapy.接受酶替代疗法的法布里病患者心肺适能与超声心动图的系列分析
J Rehabil Med Clin Commun. 2020 Feb 27;3:1000028. doi: 10.2340/20030711-1000028. eCollection 2020.
10
Sphingolipid Mediators of Myocardial Pathology.心肌病理学中的鞘脂介质
J Lipid Atheroscler. 2020 Jan;9(1):23-49. doi: 10.12997/jla.2020.9.1.23. Epub 2019 Nov 25.
本文引用的文献
1
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.晚发性肥厚型心肌病男性患者中安德森-法布里病的患病率。
Circulation. 2002 Mar 26;105(12):1407-11. doi: 10.1161/01.cir.0000012626.81324.38.
2
Enzyme-replacement therapy for Anderson-Fabry disease.安德森-法布里病的酶替代疗法。
Lancet. 2001 Aug 25;358(9282):601-3. doi: 10.1016/S0140-6736(01)05816-0.
3
Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy.半乳糖输注疗法改善法布里病心脏变异型的心脏功能。
N Engl J Med. 2001 Jul 5;345(1):25-32. doi: 10.1056/NEJM200107053450104.
4
Enzyme replacement therapy in Fabry disease: a randomized controlled trial.法布里病的酶替代疗法：一项随机对照试验。
JAMA. 2001 Jun 6;285(21):2743-9. doi: 10.1001/jama.285.21.2743.
5
An atypical variant of Fabry's disease in men with left ventricular hypertrophy.患有左心室肥厚的男性中的一种非典型法布里病变体。
N Engl J Med. 1995 Aug 3;333(5):288-93. doi: 10.1056/NEJM199508033330504.
Zotero 插件